Peter Mulders

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski et al. · The Lancet · 2008 · 330 citations

Medicine, Immunology, Oncology +16

Inter-individual differences in human brain structure and morphology link to variation in demographics and behavior

Alberto Llera, Thomas Wolfers, Peter Mulders et al. · eLife · 2019 · 127 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

Brian Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard et al. · The Lancet Oncology · 2024 · 127 citations · Full text

Medicine, Nuclear Medicine, Oncology +13

Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.

Howard I. Scher, Karim Fizazi, Fred Saad et al. · Journal of Clinical Oncology · 2012 · 117 citations

Medicine, Oncology, Pharmacology +13

Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-<i>cis</i>-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)

Nina Aass, P.H.M. de Mulder, G. Mickisch et al. · Journal of Clinical Oncology · 2005 · 98 citations · Full text

Medicine, Oncology, Pharmacology +14